Ying Huang
Vice President, CMC Biologics Crescent Biopharma
Ying is a biopharmaceutical R&D and manufacturing leader with over 20 years of post-PhD experience in biologics development. She currently serves as VP, CMC Biologics at Crescent Bio, with deep expertise in CMC strategy and execution for complex modalities including bispecific antibodies, fusion proteins, and ADCs. She has led integrated CMC programs from preclinical development through IND and BLA submissions across WuXi Biologics, Merck, GSK, KBI Biopharma, and Thermo Fisher. Her experience spans recombinant protein expression, developability assessment, cell line development, process optimization, and end-to-end CMC management supporting global regulatory filings. Ying holds a PhD in Molecular and Cell Biology from the University of Tokyo.
Seminars
- Roundtable discussions are designed to be interactive, discursive deep dives where delegates break into smaller groups to explore a focused topic through candid, peer-led conversation. Each group will exchange experiences, challenges, and practical insights before reconvening to share key takeaways with the wider audience and with the conversation being facilitated by our seminar day leaders.
- Accelerating biologics CMC timelines through strategic, risk-based development approaches
- Balancing purification efficiency, manufacturability, and product variant control
- De-risking late-stage development through early product and process understanding
